Psoriatic arthropathy
Not recruitingStudy on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors
Study on Deucravacitinib and Apremilast for Patients with Active Psoriatic Arthritis New to Biologic Treatments or Previously on TNFα Inhibitors
- Disease:Psoriatic arthropathy
- Substances:ApremilastDeucravacitinib
Hungary- Participants:18–64 years · 65+ years
- Substances:Apremilast
- Sponsor:Bristol-Myers Squibb Services Unlimited Company









